CSL Inks $US328 Million Biotech Collaboration

CSL has entered into an early-stage development collaboration and option agreement with Memo Therapeutics, a Swiss ...
PharmTech

Lilly and CSL Partner on Clazakizumab Antibody Development

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly ...
GEN

Genezen Licenses CSL’s Cytegrity Lentiviral Vector Production System

Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...
Morningstar

CSL’s Strategy Beyond Plasma Sets It Up for Sustained Growth

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...
Bloomberg L.P.

Australia’s CSL to Invest $1.5 Billion in US Drug Manufacturing

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...
Morningstar

Company Reports

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...